Black Diamond Therapeutics, Inc.
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a BDTX research report →
Companywww.blackdiamondtherapeutics.com
Black Diamond Therapeutics, Inc. , a biotechnology company, discover, develops, and commercializes medicines for patient with genetically defined tumors. It develops BDTX-189, an irreversible small molecule inhibitor that is designed to targets oncogenic proteins defined by the non-canonical epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor 2 driver mutations.
- CEO
- Mark A. Velleca
- IPO
- 2020
- Employees
- 24
- HQ
- Cambridge, MA, US
Price Chart
Valuation
- Market Cap
- $206.29M
- P/E
- -4.77
- P/S
- 0.00
- P/B
- 1.98
- EV/EBITDA
- -4.81
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- -36.37%
- ROIC
- -43.60%
Growth & Income
- Revenue
- $70.00M · 0.00%
- Net Income
- $22.37M · 132.10%
- EPS
- $0.39 · 130.71%
- Op Income
- $19.87M
- FCF YoY
- 147.53%
Performance & Tape
- 52W High
- $4.94
- 52W Low
- $1.93
- 50D MA
- $2.58
- 200D MA
- $2.94
- Beta
- 3.35
- Avg Volume
- 784.25K
Get TickerSpark's AI analysis on BDTX
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Recent Insider Transactions
| Date | Insider | Type | Shares |
|---|---|---|---|
| Mar 20, 26 | Behbahani Ali | other | 6,919 |
| Mar 20, 26 | Raman Prakash | other | 6,105 |
| Jan 21, 26 | Jones Erika | other | 200,000 |
| Jan 21, 26 | Hatzis-Schoch Brent | other | 250,000 |
| Jan 21, 26 | Buck Elizabeth | other | 250,000 |
| Jan 21, 26 | Yurasov Sergey | other | 250,000 |
| Jan 21, 26 | Velleca Mark A. | other | 600,000 |
| Dec 12, 25 | Behbahani Ali | other | 5,208 |
| Dec 12, 25 | Raman Prakash | other | 4,665 |
| Sep 19, 25 | Behbahani Ali | other | 4,291 |
Our BDTX Coverage
We haven't published any research on BDTX yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate BDTX Report →